18F NaF PET/CT in the assessment of metastatic bone disease: Comparison with specific PET tracers

PET Clinics

Volumn 7, Issue 3, 2012, Pages 303-314

  Beheshti, Mohsen ^a   Langsteger, Werner ^a  

^a St Vincent's Hospital   (Austria)

Author keywords

18F NaF PET; Choline derivatives; Fluorodeoxyglucose; Skeletal metastases; Specific PET tracers

Indexed keywords

6ALPHA FLUORO 17BETA ESTRADIOL F 18; CHOLINE C 11; CHOLINE F 18; FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; FLUOROMETHYLCHOLINE F 18; MEDRONATE TECHNETIUM TC 99M; METHIONINE C 11; SODIUM FLUORIDE F 18; TRACER; UNCLASSIFIED DRUG;

BONE METASTASIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG UPTAKE; EARLY DIAGNOSIS; HUMAN; NONHUMAN; OSTEOSCLEROSIS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

EID: 84862875473     PISSN: 15568598     EISSN: 18799809     Source Type: Journal    
DOI: 10.1016/j.cpet.2012.04.002     Document Type: Review

References (88)

1. O. Warburg On the origin of cancer cells Science 123 3191 1956 309 314
2. M. Cimitan, R. Bortolus, and S. Morassut [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 12 2006 1387 1398 (Pubitemid 44885404)
3. 18F-fluorocholine PET J Nucl Med 47 2 2006 262 269 (Pubitemid 46780891)
4. 11C-choline PET/CT J Nucl Med 47 8 2006 1249 1254 (Pubitemid 47544875)
5. 11C]choline J Nucl Med 38 6 1997 842 847 (Pubitemid 27251970)
6. T. Hara, N. Kosaka, and H. Kishi PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 6 1998 990 995 (Pubitemid 28270113)
7. 11C-choline PET J Nucl Med 41 9 2000 1507 1513
8. O. Kobori, Y. Kirihara, and N. Kosaka Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging Cancer 86 9 1999 1638 1648 (Pubitemid 29513031)
9. G. Bauman, T. Belhocine, and M. Kovacs (18)F-fluorocholine for prostate cancer imaging: a systematic review of the literature Prostate Cancer Prostatic Dis 15 1 2012 45 55
10. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer J Nucl Med 43 1 2002 46 55 (Pubitemid 34101187)
11. 11C-methionine positron emission tomography J Urol 173 1 2005 66 69 [discussion: 69] (Pubitemid 39627673)
12. T.A. Bonasera, J.P. O'Neil, and M. Xu Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons J Nucl Med 37 6 1996 1009 1015 (Pubitemid 126447143)
13. S. Vallabhajosula (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization Semin Nucl Med 37 6 2007 400 419 (Pubitemid 47505221)
14. R.E. Coleman Skeletal complications of malignancy Cancer 80 Suppl 8 1997 1588 1594 (Pubitemid 27444031)
15. J.R. Berenson, L. Rajdev, and M. Broder Pathophysiology of bone metastases Cancer Biol Ther 5 9 2006 1078 1081 (Pubitemid 44772214)
16. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2007 CA Cancer J Clin 57 1 2007 43 66 (Pubitemid 46148091)
17. M. Blau, W. Nagler, and M.A. Bender Fluorine-18: a new isotope for bone scanning J Nucl Med 3 1962 332 334
18. 18F PET J Nucl Med 40 10 1999 1623 1629 (Pubitemid 29471151)
19. I. Fogelman, G. Cook, and O. Israel Positron emission tomography and bone metastases Semin Nucl Med 35 2 2005 135 142 (Pubitemid 40568746)
20. 18F-fluoride measured with positron emission tomography in correlation with CT Skeletal Radiol 27 2 1998 72 76 (Pubitemid 28181733)
21. R.A. Hawkins, Y. Choi, and S.C. Huang Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET J Nucl Med 33 5 1992 633 642
22. H. Schirrmeister, A. Guhlmann, and J. Kotzerke Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography J Clin Oncol 17 8 1999 2381 2389 (Pubitemid 29368236)
23. 18F-fluoride in bone imaging with emphasis on prostate and breast Semin Nucl Med 36 1 2006 73 92 (Pubitemid 41782168)
24. M. Beheshti, W. Langsteger, and I. Fogelman Prostate cancer: role of SPECT and PET in imaging bone metastases Semin Nucl Med 39 6 2009 396 407
25. H. Schirrmeister Detection of bone metastases in breast cancer by positron emission tomography Radiol Clin North Am 45 4 2007 669 676 vi (Pubitemid 47238392)
26. H. Minn, A.C. Clavo, and R.L. Wahl Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging Nucl Med Biol 23 8 1996 941 946 (Pubitemid 27050680)
27. S. Ben-Haim, and O. Israel Breast cancer: role of SPECT and PET in imaging bone metastases Semin Nucl Med 39 6 2009 408 415
28. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions J Clin Oncol 16 10 1998 3375 3379 (Pubitemid 28481635)
29. M. Ohta, Y. Tokuda, and Y. Suzuki Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy Nucl Med Commun 22 8 2001 875 879 (Pubitemid 32681625)
30. S.N. Yang, J.A. Liang, and F.J. Lin Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer J Cancer Res Clin Oncol 128 6 2002 325 328
31. S. Mahner, S. Schirrmacher, and W. Brenner Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer Ann Oncol 19 7 2008 1249 1254 (Pubitemid 351911953)
32. T. Uematsu, S. Yuen, and S. Yukisawa Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer AJR Am J Roentgenol 184 4 2005 1266 1273 (Pubitemid 43821911)
33. T. Nakai, C. Okuyama, and T. Kubota Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer Eur J Nucl Med Mol Imaging 32 11 2005 1253 1258 (Pubitemid 41598715)
34. A. Iagaru, E. Mittra, and D.W. Dick Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases Mol Imaging Biol 14 2 2012 252 259
35. G. Singh, C.L. Lakkis, and R. Laucirica Regulation of prostate cancer cell division by glucose J Cell Physiol 180 3 1999 431 438 (Pubitemid 29334844)
36. F. Rossi, M. Grzeskowiak, and V. Della Bianca De novo synthesis of diacylglycerol from glucose. A new pathway of signal transduction in human neutrophils stimulated during phagocytosis of beta-glucan particles J Biol Chem 266 13 1991 8034 8038 (Pubitemid 21906470)
37. P.J. Effert, R. Bares, and S. Handt Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose J Urol 155 3 1996 994 998
38. 18F]fluoro-D-glucose Radiology 199 3 1996 751 756
39. S.D. Yeh, M. Imbriaco, and S.M. Larson Detection of bony metastases of androgen-independent prostate cancer by PET-FDG Nucl Med Biol 23 6 1996 693 697 (Pubitemid 26342473)
40. M.A. Seltzer, Z. Barbaric, and A. Belldegrun Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer J Urol 162 4 1999 1322 1328 (Pubitemid 29428572)
41. 11C-acetate PET imaging of prostate cancer J Nucl Med 43 2 2002 181 186 (Pubitemid 34151040)
42. D.B. Agus, D.W. Golde, and G. Sgouros Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal Cancer Res 58 14 1998 3009 3014 (Pubitemid 28335080)
43. M.M. Steinborn, A.F. Heuck, and R. Tiling Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system J Comput Assist Tomogr 23 1 1999 123 129 (Pubitemid 29095482)
44. M. Hetzel, J. Hetzel, and C. Arslandemir Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: prospective study BMJ 328 7447 2004 1051 1052 (Pubitemid 38580828)
45. H. Schirrmeister, C. Arslandemir, and G. Glatting Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer Eur J Nucl Med Mol Imaging 31 7 2004 964 968 (Pubitemid 38915651)
46. M.J. Morris, T. Akhurst, and I. Osman Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer Urology 59 6 2002 913 918 (Pubitemid 34522186)
47. 11C]choline does not correlate with cell proliferation in human prostate cancer Eur J Nucl Med Mol Imaging 32 6 2005 668 673 (Pubitemid 40897489)
48. 11C]Choline as a PET biomarker for assessment of prostate cancer tumor models Bioorg Med Chem 12 11 2004 2887 2893 (Pubitemid 38622124)
49. T. Hara, N. Kosaka, and H. Kishi Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging J Nucl Med 43 2 2002 187 199 (Pubitemid 34151041)
50. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer Cancer Res 61 1 2001 110 117 (Pubitemid 32095708)
51. T.R. DeGrado, S.W. Baldwin, and S. Wang Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers J Nucl Med 42 12 2001 1805 1814 (Pubitemid 34016349)
52. 18F-fluorocholine J Nucl Med 43 1 2002 92 96 (Pubitemid 34102997)
53. W. Langsteger, M. Beheshti, and M. Nader Evaluation of lymph node and bone metastases with Fluor Choline (FCH) PET-CT in the follow up of prostate cancer patients Eur J Nucl Med Mol Imaging 33 Suppl 2 2006 209
54. W. Langsteger, M. Beheshti, and W. Loidl Fluor Choline (FCH) PET-CT in preoperative staging of prostate cancer Eur J Nucl Med Mol Imaging 33 Suppl 2 2006 207 208
55. 18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer Eur J Nucl Med Mol Imaging 34 8 2007 1316 1317 [author reply: 1318-9] (Pubitemid 47290667)
56. D.B. Husarik, R. Miralbell, and M. Dubs Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 2 2008 253 263
57. 18F choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT Mol Imaging Biol 11 6 2009 446 454
58. W. Langsteger, M. Beheshti, and S. Pöcher Fluor Choline (FCH) PET-CT in preoperative staging and follow up of prostate cancer Mol Imaging Biol 8 2006 69
59. M. Beheshti, S. Haim, and M. Nader Assessment of bone metastases in patients with prostate cancer by dual-phase F-18 Fluor Choline PET/CT Eur J Nucl Med Mol I 33 Suppl 2 2006 208
60. 18F fluoride PET-CT: a comparative study Eur J Nucl Med Mol Imaging 35 10 2008 1766 1774
61. A. Alavi, J.W. Kung, and H. Zhuang Implications of PET based molecular imaging on the current and future practice of medicine Semin Nucl Med 34 1 2004 56 69 (Pubitemid 38056404)
62. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients Radiology 254 3 2010 925 933
63. 11C]choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy Eur J Nucl Med Mol Imaging 39 1 2012 13 26
64. M. Beheshti, and W. Langsteger Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients Eur J Nucl Med Mol Imaging 39 5 2012 910 911
65. L.C. Costello, and R.B. Franklin Citrate metabolism of normal and malignant prostate epithelial cells Urology 50 1 1997 3 12 (Pubitemid 27300357)
66. M. Yoshimoto, A. Waki, and Y. Yonekura Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells Nucl Med Biol 28 2 2001 117 122 (Pubitemid 32276075)
67. P.D. Shreve, and M.D. Gross Imaging of the pancreas and related diseases with PET carbon-11-acetate J Nucl Med 38 8 1997 1305 1310 (Pubitemid 27332636)
68. P. Shreve, P.C. Chiao, and H.D. Humes Carbon-11-acetate PET imaging in renal disease J Nucl Med 36 9 1995 1595 1601
69. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse J Nucl Med 44 4 2003 549 555 (Pubitemid 39663421)
70. J. Kotzerke, B.G. Volkmer, and B. Neumaier Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer Eur J Nucl Med Mol Imaging 29 10 2002 1380 1384 (Pubitemid 44392221)
71. S. Albrecht, F. Buchegger, and D. Soloviev (11)C-acetate PET in the early evaluation of prostate cancer recurrence Eur J Nucl Med Mol Imaging 34 2 2007 185 196 (Pubitemid 46147501)
72. 11C-acetate J Nucl Med 48 3 2007 420 428 (Pubitemid 47604928)
73. 18F-fluoroacetate using PET/CT Eur J Nucl Med Mol Imaging 31 5 2004 797 (Pubitemid 38647921)
74. A.V. Mitra, E.K. Bancroft, and Y. Barbachano Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study BJU Int 107 1 2011 28 39
75. 11C]methionine Int J Rad Appl Instrum A 39 4 1988 311 314
76. H. Miyazawa, T. Arai, and M. Iio PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters J Nucl Med 34 11 1993 1886 1891 (Pubitemid 23331252)
77. B. Goudarzi, R. Kishimoto, and S. Komatsu Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy Magn Reson Imaging 28 3 2010 372 379
78. A.B. Apolo, N. Pandit-Taskar, and M.J. Morris Novel tracers and their development for the imaging of metastatic prostate cancer J Nucl Med 49 12 2008 2031 2041
79. H.I. Scher, and C.L. Sawyers Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 23 32 2005 8253 8261 (Pubitemid 46211563)
80. 18F-FDG in patients with progressive, metastatic prostate cancer J Nucl Med 45 3 2004 366 373 (Pubitemid 47618608)
81. F. Dehdashti, J. Picus, and J.M. Michalski Positron tomographic assessment of androgen receptors in prostatic carcinoma Eur J Nucl Med Mol Imaging 32 3 2005 344 350 (Pubitemid 40562127)
82. C. Van de Wiele, F. De Vos, and G. Slegers Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review Eur J Nucl Med 27 9 2000 1421 1433
83. S. Mosselman, J. Polman, and R. Dijkema ER beta: identification and characterization of a novel human estrogen receptor FEBS Lett 392 1 1996 49 53 (Pubitemid 26268330)
84. E.V. Jensen, E.R. Desombre, and T. Kawashima Estrogen-binding substances of target tissues Science 158 3800 1967 529 530
85. D.A. Mankoff, A.F. Shields, and K.A. Krohn PET imaging of cellular proliferation Radiol Clin North Am 43 1 2005 153 167 (Pubitemid 40326566)
86. D.O. Kiesewetter, M.R. Kilbourn, and S.W. Landvatter Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats J Nucl Med 25 11 1984 1212 1221 (Pubitemid 15214135)
87. M.A. Mintun, M.J. Welch, and B.A. Siegel Breast cancer: PET imaging of estrogen receptors Radiology 169 1 1988 45 48
88. M. van Kruchten, A.W. Glaudemans, and E.F. de Vries PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma J Nucl Med 53 2 2012 182 190